Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial
(2022)
Journal Article
Abhishek, A., Boyton, R. J., Peckham, N., McKnight, Á., Coates, L. C., Bluett, J., Barber, V., Cureton, L., Francis, A., Appelbe, D., Eldridge, L., Julier, P., Valdes, A. M., Brooks, T., Rombach, I., Altmann, D. M., Nguyen-Van-Tam, J. S., Williams, H. C., & Cook, J. A. (2022). Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respiratory Medicine, 10(9), 840-850. https://doi.org/10.1016/S2213-2600%2822%2900186-2
Background: Immunosuppressive treatments inhibit vaccine-induced immunity against SARS-CoV-2. We evaluated whether a 2-week interruption of methotrexate treatment immediately after the COVID-19 vaccine booster improved antibody responses against the... Read More about Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.